<DOC>
	<DOCNO>NCT02646020</DOCNO>
	<brief_summary>Study hypothesis aprepitant effective desloratadine relieve pruritus cause EGFR TKIs . Primary endpoint effective rate pruritus , effective treatment define visual analogue scale ( VAS ) decrease ≥ 50 % treatment compare baseline score . 130 NSCLC patient undertaken EGFR-TKI suffer moderate severe pruritus ( VAS score ≥ 4 ) enrol study , stratify ( gender , first seconde generation TKIs , VAS 4-6 7-10 ) randomize ( 1:1 ) aprepitant desloratadine treatment . VAS investigation take week treatment end follow-up end ( ≤12 week ) .</brief_summary>
	<brief_title>Aprepitant vs. Desloratadine EGFR-TKIs Related Pruritus Treatment</brief_title>
	<detailed_description>This prospective , randomize control , double-blinded , phase II clinical trial . Study hypothesis aprepitant effective desloratadine relieve pruritus cause EGFR TKIs . Primary endpoint effective rate pruritus , effective treatment define visual analogue scale ( VAS ) decrease ≥ 50 % treatment compare baseline score . Secondary endpoint duration pruritus relieving , define time pruritus effective relief VAS score increase ≥ baseline level , VAS inquiry take week , treatment last 28 day unless pruritus recurrence discontinuation EGFR-TKI . Quality life investigation perform baseline , treatment end follow-up end use SKINDEX-16 questionnaire . 130 NSCLC patient undertaken EGFR-TKI suffer moderate severe pruritus ( VAS score ≥ 4 ) enrol study , stratify ( gender , first seconde generation TKIs , VAS 4-6 7-10 ) randomize ( 1:1 ) aprepitant desloratadine treatment . Aprepitant arm administrate aprepitant 125mg d1 , 80mg d3 d5 , along placebo 5mg d1-d28 ; desloratadine arm administrate placebo 125mg d1 , 80mg d3 d5 , along desloratadine 5mg d1-d28 . Tolerance evaluation take accord National Cancer Institute ( NCI ) -Common Terminology Criteria ( CTC ) For Adverse Events ( AE ) V4.03 . Treatment end d28 , VAS investigation take week treatment end , treatment effective , patient unblinded receive treatment decide investigator . If treatment effective , follow-up take 12 week</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Advanced metastatic non small cell lung cancer Harboured positive EGFR mutation ( 19del , 21L858R , 21861Q , etc ) Undertaken EGFR TKIs treatment ( gefitinib , erlotinib , icotinib , afatinib , etc ) 18 year old Eastern Cooperative Oncology Group ( ECOG ) performance score 02 Moderate severe pruritus ( VAS score ≥ 4 ) first occur EGFR TKIs treatment Life expectancy ≥ 3 month Orally drug administration difficulty pregnancy test negative 7 day woman childbearing age ; willing take contraception measure . Signed informed consent form ( ICF ) Systemically treatment Neurokinin1 ( NK1 ) receptor inhibitor , antihistamine drug , antibiotic , cortical hormone therapy , antiepileptic drug , immunosuppressive agent drug might affect treatment 4 week ; locally use drug 2 week . Existing skin lesion EGFR TKIs relate , skin infection , chronic dermatitis , Systemic Lupus Erythematosus ( SLE ) , lymphoma disease . Total bilirubin ≥ 1.5 Upper Limit Of Normal ( ULN ) Serum creatinine ≥mg/dl AST ALT ≥ 2.5 ULN without liver metastasis ; ≥ 5 ULN liver metastasis . Residual toxicity event ≥ CTCAE grade 2 , except peripheral neurotoxicities . Central nervous system ( CNS ) metastasis spinal compression ; except symptom cortical hormonotherapy 4 week . Clinical evidence interstitial lung disease Any severe uncontrolled systemic disease judge investigator . Any contraindication Neurokinin1 receptor inhibitor desloratadine . Discontinuation Criteria Invalid subject randomization Major protocol violation judge investigator . Poor compliance Intolerable adverse event Subject withdraw ICF Any pregnancy event No clinical benefit due clinical adverse event , laboratory abnormality medical condition Other reason treatment discontinuation judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>pruritus</keyword>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>Receptor , Epidermal Growth Factor</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
</DOC>